HRAS and cancer: Gene alterations of cancer-associated genes (oncogenic drivers and tumor suppressors) such as TP53 (tumor protein p53), CDKN2A (cyclin-dependent kinase inhibitor 2A), HRAS (HRas proto-oncogene, GTPase), EGFR (epidermal growth factor receptor), and Rb1 (Retinoblastoma 1) have also been mentioned [27,28,29,30].